Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 198

1.

The Urine Preservative Acetic Acid Degrades Urine Protein: Implications for Urine Biorepositories and the AASK Cohort Study.

Almaani S, Hebert LA, Rovin BH, Birmingham DJ.

J Am Soc Nephrol. 2017 Jan 19. pii: ASN.2016080886. doi: 10.1681/ASN.2016080886. [Epub ahead of print]

PMID:
28104821
2.

Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of ANA and anti-DNA.

Pisetsky DS, Rovin BH, Lipsky PE.

Arthritis Rheumatol. 2016 Nov 29. doi: 10.1002/art.40008. [Epub ahead of print] Review. No abstract available.

PMID:
27899010
3.

Molecular imaging of the kidney in lupus nephritis to characterize response to treatment.

Parikh SV, Malvar A, Song H, Alberton V, Lococo B, Vance J, Zhang J, Yu L, Birmingham D, Rovin BH.

Transl Res. 2016 Nov 1. pii: S1931-5244(16)30317-6. doi: 10.1016/j.trsl.2016.10.010. [Epub ahead of print]

PMID:
27842222
4.

A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.

Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC.

J Am Soc Nephrol. 2016 Nov 7. pii: ASN.2016060640. [Epub ahead of print]

PMID:
27821627
5.

Update on Lupus Nephritis.

Almaani S, Meara A, Rovin BH.

Clin J Am Soc Nephrol. 2016 Nov 7. pii: CJN.05780616. [Epub ahead of print]

PMID:
27821390
6.

Staphylococcus Infection-Associated GN - Spectrum of IgA Staining and Prevalence of ANCA in a Single-Center Cohort.

Satoskar AA, Suleiman S, Ayoub I, Hemminger J, Parikh S, Brodsky SV, Bott C, Calomeni E, Nadasdy GM, Rovin B, Hebert L, Nadasdy T.

Clin J Am Soc Nephrol. 2017 Jan 6;12(1):39-49. doi: 10.2215/CJN.05070516.

PMID:
27821389
7.

The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials.

Rovin BH, Dooley MA, Radhakrishnan J, Ginzler EM, Forrester TD, Anderson PW.

Lupus. 2016 Dec;25(14):1597-1601.

PMID:
27220348
8.

The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Cartin-Ceba R, Indrakanti D, Specks U, Stone JH, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Spiera RF, Monach PA, St Clair EW, Seo P, Tchao NK, Ytterberg SR, Brunetta PG, Song H, Birmingham D, Rovin BH; RAVE-Immune Tolerance Network Research Group..

Arthritis Rheumatol. 2017 Jan;69(1):169-175. doi: 10.1002/art.39822.

PMID:
27482943
9.

The interleukin-6-hepcidin-hemoglobin circuit in systemic lupus erythematosus flares.

Indrakanti DL, Alvarado A, Zhang X, Birmingham DJ, Hinton A, Rovin BH.

Lupus. 2016 Jul 14. pii: 0961203316659153. [Epub ahead of print]

PMID:
27416847
10.

A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis.

Anders HJ, Rovin B.

Kidney Int. 2016 Sep;90(3):493-501. doi: 10.1016/j.kint.2016.05.017. Review.

PMID:
27378475
11.

Current and Emerging Therapies for Lupus Nephritis.

Parikh SV, Rovin BH.

J Am Soc Nephrol. 2016 Oct;27(10):2929-2939.

PMID:
27283496
12.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.

Rovin BH, van Vollenhoven RF, Aranow C, Wagner C, Gordon R, Zhuang Y, Belkowski S, Hsu B.

Arthritis Rheumatol. 2016 Sep;68(9):2174-83. doi: 10.1002/art.39722.

13.

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

Ayoub I, Hebert L, Rovin BH.

N Engl J Med. 2016 Mar 10;374(10):991-2. doi: 10.1056/NEJMc1600141#SA2. No abstract available.

PMID:
26962738
14.

Predicting decline of kidney function in lupus nephritis using urine biomarkers.

Abulaban KM, Song H, Zhang X, Kimmel PL, Kusek JW, Nelson RG, Feldman HI, Vasan RS, Ying J, Mauer M, Nelsestuen GL, Bennett M, Brunner HI, Rovin BH.

Lupus. 2016 Aug;25(9):1012-8. doi: 10.1177/0961203316631629.

PMID:
26873651
15.

Hurdles to the introduction of new therapies for immune-mediated kidney diseases.

Anders HJ, Jayne DR, Rovin BH.

Nat Rev Nephrol. 2016 Apr;12(4):205-16. doi: 10.1038/nrneph.2015.206. Review.

PMID:
26804020
16.

Quiz Page February 2016: Acute Kidney Injury in a Patient With Granulomatosis With Polyangiitis Receiving Maintenance Immunosuppressive Therapy.

Ayoub I, Almaani S, Alvarado A, Parikh SV, Rovin BH.

Am J Kidney Dis. 2016 Feb;67(2):A20-3. doi: 10.1053/j.ajkd.2015.10.017. No abstract available.

PMID:
26802333
17.

Revisiting medullary tophi: a link between uric acid and progressive chronic kidney disease?

Ayoub I, Almaani S, Brodsky S, Nadasdy T, Prosek J, Hebert L, Rovin B.

Clin Nephrol. 2016 Feb;85(2):109-13. doi: 10.5414/CN108663.

PMID:
26709523
18.

Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare.

Birmingham DJ, Bitter JE, Ndukwe EG, Dials S, Gullo TR, Conroy S, Nagaraja HN, Rovin BH, Hebert LA.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):47-53. doi: 10.2215/CJN.03990415.

19.

A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial.

Tamirou F, Lauwerys BR, Dall'Era M, Mackay M, Rovin B, Cervera R, Houssiau FA; MAINTAIN Nephritis Trial Investigators..

Lupus Sci Med. 2015 Nov 12;2(1):e000123. doi: 10.1136/lupus-2015-000123.

20.

Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders.

Parikh SV, Malvar A, Song H, Alberton V, Lococo B, Vance J, Zhang J, Yu L, Rovin BH.

Lupus Sci Med. 2015 Nov 18;2(1):e000112. doi: 10.1136/lupus-2015-000112.

Items per page

Supplemental Content

Loading ...
Support Center